UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~July 269, 2026

Biohaven Ltd.

(Exact name of registrant as specified in its charter)


British Virgin Islands	001-41477	Not applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

(203) 404-0410

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of each exchange on which registered
Common Shares, no par value	BHVN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0102 Departure ~~Regulation~~of FDDirectors ~~Disclosure~~or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~May~~July 269, 2026, Biohaven Ltd. (the “~~Registrant~~Company”) ~~issued~~and aBruce ~~press~~Car, ~~release~~Ph.D., ~~reporting~~mutually ~~new~~agreed ~~clinical~~that, ~~data~~effective inJuly ~~epilepsy~~13, ~~with~~2026, ~~opakalim~~Dr. ACar ~~copy~~will retire as Chief Scientific Officer of ~~this~~the ~~press~~Company ~~release~~and iswill ~~furnished~~remain ~~herewith~~with the Company as ~~Exhibit~~a 99part-time employee in the newly created role of Chief Innovation Officer.1 As Chief Innovation Officer, Dr. Car will focus on advancing Biohaven’s scientific initiatives and external collaborations, including leading multiple assets under the Company’s collaboration with Bexorg, Inc. Dr. Car will continue to serve as an executive officer of the Company. In connection with this ~~Current~~transition, ~~Report~~David Pirman, Ph.D., has been promoted to Executive Vice President and isHead ~~incorporated~~of ~~herein~~Discovery, byeffective ~~reference~~July 13, 2026. In this role, Dr. Pirman will lead the Company’s internal drug-discovery organization, overseeing research programs.

OnIn ~~May~~connection ~~27,~~with ~~2026,~~his ~~the~~transition ~~Registrant~~to ~~issued~~ a ~~press~~part-time ~~release~~role, ~~reporting positive clinical biomarker and patient data~~Dr. ACar’s ~~copy~~salary ofwill ~~this~~be ~~press~~reduced ~~release~~by isfifty ~~furnished~~percent ~~herewith~~(50%) ~~as Exhibit 99.2~~ to ~~this~~reflect ~~Current~~his ~~Report~~work ~~and is incorporated herein by reference~~schedule.

OnThere ~~May~~are ~~27,~~no ~~2026,~~arrangements ~~the~~or ~~Registrant~~understandings ~~made~~between aDr. ~~presentation~~Car ~~(the~~and ~~“Presentation”)~~any atother ~~its~~persons ~~annual~~pursuant ~~R&D~~to ~~Day~~which ~~held~~he inagreed ~~conjunction~~to ~~with~~transition ~~the~~to ~~Yale~~a ~~Innovation~~part-time ~~Summit~~role. atThere ~~the~~are ~~Yale~~no ~~School~~related ofparty ~~Management~~transactions inbetween ~~New Haven, Connecticut~~Dr. ACar ~~copy~~and of the ~~Presentation~~Company isthat ~~attached~~would asrequire ~~Exhibit~~disclosure ~~99.3~~under toItem ~~this~~401(a) ~~Current~~of ~~Report~~Regulation ~~on Form 8~~S-K~~, and is incorporated herein by reference~~.

~~The~~A ~~information~~copy inof ~~this Current Report on Form 8-K, including~~ the ~~information~~press ~~set~~release ~~forth~~issued inby ~~Exhibits 99.1, 99.2 and 99.3 is being furnished and shall not be deemed “filed” for purposes of Section 18 of~~ the ~~Securities~~Company ~~Exchange~~on ~~Act~~July ~~of 1934~~9, ~~as amended (the “Exchange Act”)~~2026, ~~nor~~announcing ~~shall it be deemed incorporated by reference in any filing under~~ the ~~Securities~~transition ~~Act~~ of ~~1933,~~Dr. asCar ~~amended,~~is orattached ~~the~~hereto ~~Exchange~~as ~~Act,~~Exhibit ~~except~~99.1 asto ~~shall~~this beCurrent ~~expressly~~Report ~~set~~on ~~forth~~Form by8-K ~~specific~~and ~~reference~~is inincorporated ~~such~~herein aby ~~filing~~reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Exhibit Description
99.1						Press Release, Dated ~~May~~July 269, 2026, “Biohaven ~~Reports~~Announces ~~New~~Scientific ~~Clinical~~Leadership ~~Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile"~~Transitions”
99.2						Press Release, Dated May 27, 2026, “Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy”
99.3						Investor Presentation, May 2026.
104						The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~May~~July 279, 2026


Biohaven Ltd.

By:			/s/ Matthew Buten
			Matthew Buten
			Chief Financial Officer

Filing Compare · Biohaven Ltd.